Skye Bioscience, Inc. current report, 29 January 2024

Full document

Business Context and Reporting Period

Company: Skye Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date: January 29, 2024
Event: Entry into a Material Definitive Agreement for a private placement financing (PIPE).

Key Financial Metrics

Capital Raised: The Company expects to receive aggregate gross proceeds of approximately $50,250,000 from the Private Placement, before deducting placement agent fees and offering expenses.
Securities Issued:

  • 11,822,124 shares of Common Stock at $2.305 per share.
  • Pre-funded warrants to purchase up to 9,978,739 shares of Common Stock at $2.3049 per warrant.
Liquidity Impact: Net proceeds are expected to fund operations into early 2026.
Debt and Margins: The filing text does not provide specific values for debt, revenue, profit, cash flow, or operating margins.

Material Changes and Agreements

Securities Purchase Agreement: Entered into with institutional investors on January 29, 2024. The transaction is expected to close on or about January 31, 2024.
Registration Rights: The Company must file a resale registration statement within 60 days of the agreement date and use reasonable best efforts to have it declared effective promptly thereafter.
Lock-up Agreements: Directors and officers are subject to a 90-day lock-up period following the closing of the Private Placement.
Intellectual Property Restrictions: The Company may not transfer, license, encumber, or sell royalty interests in intellectual property relating to nimacimab without written consent from Qualified Investors (holding at least 40% of Closing Securities) while they maintain their ownership threshold.

Outlook, Management Commentary, and Risks

Use of Proceeds: Funding will support operations into early 2026, covering R&D, general corporate purposes, and working capital.
Clinical Development Plan:

  • Nimacimab (Obesity): Phase 2 trial anticipated to start mid-year 2024. Design involves ~200 obese patients randomized into four arms (nimacimab, GLP-1R agonist, combination, or placebo) for 26 weeks. Interim data expected Q1 2025; topline data expected in 2025.
  • SBI-100 Ophthalmic Emulsion (Glaucoma): Phase 2a trial currently enrolling with interim data expected Q1 2024 and topline data Q2 2024. Phase 2b trial anticipated to start H2 2024 with topline data expected in 2025.
Risks and Contingencies: The Phase 2 clinical trial design for nimacimab is not finalized and remains subject to change based on advisor input and U.S. FDA feedback. The closing of the financing is subject to customary conditions, including the accuracy of representations and warranties.

Investor Verification Checklist

  • Confirm the actual closing date and final net proceeds after deducting placement agent fees and offering expenses.
  • Verify the final design and FDA acceptance of the nimacimab Phase 2 obesity trial.
  • Monitor the timeline for the filing and effectiveness of the resale registration statement for the new securities.
  • Track the 90-day lock-up expiration for directors and officers to assess potential near-term selling pressure.
  • Review the specific terms of the "Qualified Investor" consent rights regarding nimacimab intellectual property.